Concomitant administration of meningococcal vaccines with other vaccines in adolescents and adults: a review of available evidence

Abstract

Invasive meningococcal disease (IMD), a rapidly progressing and potentially fatal illness, disproportionately affects adolescents and young adults. While IMD is best prevented by vaccination, vaccine uptake in these groups is low. An evidence-based understanding of the safety and effectiveness of concomitant vaccination of meningococcal vaccines, including the newer MenB protein vaccines and the more established MenACWY conjugate vaccines, with other vaccines recommended for adolescents and young adults may help maximize vaccination opportunities. We identified 21 studies assessing concomitant administration of meningococcal vaccines with other vaccines in adolescents and adults. Although studies varied in methodology, concomitant administration generally did not affect immunogenicity of the meningococcal or coadministered vaccines. In some cases, reactogenicity increased following concomitant administration, but no definitive safety concerns were raised. In general, data suggest that meningococcal vaccines can be safely and effectively coadministered with other vaccines.

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Tdap Vaccine

“…38 , 39 Integrating the dengue vaccine with immunization programs could help reduce the morbidity and mortality rates on future epidemics. Furthermore, the findings of this study are consistent with reports indicating that vaccines, such as meningococcal 40 and human papillomavirus, 41 can be safely and effectively co-administered with other vaccines in adolescents and adults to improve vaccination rates and reduce the burden of vaccinations.…”

Meningococcal B vaccine antigen FHbp variants among disease-causing Neisseria meningitidis B isolates, Italy, 2014–2017

“…Neisseria meningitidis of serogroup B represents an major challenge in the prevention and control of invasive meningococcal disease due to this serogroup [ 1 , 2 , 4 ].…”

“…Patients with IMD may have nonspecific symptoms early in the disease, but their condition can deteriorate rapidly. Therefore, vaccination represents the optimal strategy for the prevention of IMD [1,2]. N. meningitidis serogroup B (MenB) today represents the main serogroup circulating in several European countries [3] including Italy (http://old.iss.it/binary/mabi/cont/Interim_ Report_2018_finale.pdf) given the widespread use of recommended meningococcal C vaccination in the country [4].…”

“…Patients with IMD may have nonspecific symptoms early in the disease, but their condition can deteriorate rapidly. Therefore, vaccination represents the optimal strategy for the prevention of IMD [ 1 , 2 ]. N .…”

Meningococcal Disease in Pediatric Age: A Focus on Epidemiology and Prevention

“…In a cost-effective-based vaccination strategy, to enhance compliance, another excellent aspect is the chance of co-administering the MenB vaccine with other vaccines proposed in adolescence, such as the meningococcal ACYW vaccine, Tdap-IPV and Tdap vaccines, or HPV vaccine. Since the nonavalent anti-HPV vaccine has recently been approved, data about its co-administration with the MenB vaccine are not yet available [ 81 ].…”